HCP
DFTX

Hexagon Capital Partners’s Definium Therapeutics DFTX Stock Holding History

Hexagon Capital Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4
Closed -$23 – 1072
2025
Q1 		$23 Hold
4
– – ﹤0.01% 1822
2024
Q4 		$28 Hold
4
– – ﹤0.01% 1828
2024
Q3 		$23 Hold
4
– – ﹤0.01% 1565
2024
Q2 		$29 Hold
4
– – ﹤0.01% 1442
2024
Q1 		$38 Hold
4
– – ﹤0.01% 1453
2023
Q4 		$15 Buy
+4
New +$12 ﹤0.01% 1415

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hexagon Capital Partners's DFTX Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Definium Therapeutics (DFTX) in Q2 2025, closing a stake of 4 shares — an estimated $23 sold.

Hexagon Capital Partners first reported a position in DFTX in Q4 2023 and held it in 6 quarters. The position peaked at $38 in Q1 2024. 181 funds tracked by Wall St. Rank hold DFTX as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Definium Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 4 Definium Therapeutics shares in Q2 2025, an estimated $23.
  • Hexagon Capital Partners first reported a position in Definium Therapeutics in Q4 2023 and held it in 6 quarters.
  • Hexagon Capital Partners's Definium Therapeutics position peaked at $38 in Q1 2024.
  • 181 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.